Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,865
archived clinical trials in
Multiple Sclerosis

Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated:  7/13/2016
NeuroCare Center, Inc.
mi
from
Canton, OH
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated: 7/13/2016
NeuroCare Center, Inc.
mi
from
Canton, OH
Click here to add this to my saved trials
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated:  7/13/2016
Leheigh Valley Neurosciences and Pain Research Center
mi
from
Allentown, PA
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated: 7/13/2016
Leheigh Valley Neurosciences and Pain Research Center
mi
from
Allentown, PA
Click here to add this to my saved trials
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated:  7/13/2016
Westmorland Neurology
mi
from
Greensburg, PA
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated: 7/13/2016
Westmorland Neurology
mi
from
Greensburg, PA
Click here to add this to my saved trials
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated:  7/13/2016
Neurological Associates of Delaware Valley
mi
from
Upland, PA
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated: 7/13/2016
Neurological Associates of Delaware Valley
mi
from
Upland, PA
Click here to add this to my saved trials
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated:  7/13/2016
FACH-UHC Department of Neurological Services
mi
from
Burlington, VT
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated: 7/13/2016
FACH-UHC Department of Neurological Services
mi
from
Burlington, VT
Click here to add this to my saved trials
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated:  7/13/2016
Swedish Medical Center
mi
from
Seattle, WA
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated: 7/13/2016
Swedish Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated:  7/13/2016
Neurology and Neurosurgery Associates of Tacoma
mi
from
Tacoma, WA
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status: Enrolling
Updated: 7/13/2016
Neurology and Neurosurgery Associates of Tacoma
mi
from
Tacoma, WA
Click here to add this to my saved trials
Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS
Mechanisms of Action of Dimethyl Fumarate in Relapsing MS
Status: Enrolling
Updated:  7/19/2016
Washington University (John L. Trotter MS Center)
mi
from
St. Louis, MO
Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS
Mechanisms of Action of Dimethyl Fumarate in Relapsing MS
Status: Enrolling
Updated: 7/19/2016
Washington University (John L. Trotter MS Center)
mi
from
St. Louis, MO
Click here to add this to my saved trials
Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS
Mechanisms of Action of Dimethyl Fumarate in Relapsing MS
Status: Enrolling
Updated:  7/19/2016
Swedish Neuroscience Institute
mi
from
Seattle, WA
Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS
Mechanisms of Action of Dimethyl Fumarate in Relapsing MS
Status: Enrolling
Updated: 7/19/2016
Swedish Neuroscience Institute
mi
from
Seattle, WA
Click here to add this to my saved trials
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  8/9/2016
Clinical Research Facility
mi
from
Gilbert, AZ
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 8/9/2016
Clinical Research Facility
mi
from
Gilbert, AZ
Click here to add this to my saved trials
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  8/9/2016
Clinical Research Facility
mi
from
Phoenix, AZ
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 8/9/2016
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  8/9/2016
Clinical Research Facility
mi
from
Phoenix, AZ
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 8/9/2016
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  8/9/2016
Clinical Research Facility
mi
from
Long Beach, CA
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 8/9/2016
Clinical Research Facility
mi
from
Long Beach, CA
Click here to add this to my saved trials
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  8/9/2016
Clinical Research Facility
mi
from
Miami, FL
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 8/9/2016
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  8/9/2016
Clinical Research Facility
mi
from
West Palm Beach, FL
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 8/9/2016
Clinical Research Facility
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  8/9/2016
Clinical Research Facility
mi
from
Avon, IN
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 8/9/2016
Clinical Research Facility
mi
from
Avon, IN
Click here to add this to my saved trials
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  8/9/2016
Clinical Research Facility
mi
from
Franklin, IN
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 8/9/2016
Clinical Research Facility
mi
from
Franklin, IN
Click here to add this to my saved trials
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  8/9/2016
Clinical Research Facility
mi
from
Indianapolis, IN
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 8/9/2016
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  8/9/2016
Clinical Research Facility
mi
from
Overland Park, KA
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 8/9/2016
Clinical Research Facility
mi
from
Overland Park, KA
Click here to add this to my saved trials
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  8/9/2016
Clinical Research Facility
mi
from
Auburn, ME
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 8/9/2016
Clinical Research Facility
mi
from
Auburn, ME
Click here to add this to my saved trials
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  8/9/2016
Clinical Research Facility
mi
from
Asheville, NC
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 8/9/2016
Clinical Research Facility
mi
from
Asheville, NC
Click here to add this to my saved trials
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  8/9/2016
Clinical Research Facility
mi
from
Charlotte, NC
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 8/9/2016
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  8/9/2016
Clinical Research Facility
mi
from
Raleigh, NC
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 8/9/2016
Clinical Research Facility
mi
from
Raleigh, NC
Click here to add this to my saved trials
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  8/9/2016
Clinical Research Facility
mi
from
Wilmington, NC
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 8/9/2016
Clinical Research Facility
mi
from
Wilmington, NC
Click here to add this to my saved trials
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  8/9/2016
Clinical Research Facility
mi
from
Dayton, OH
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 8/9/2016
Clinical Research Facility
mi
from
Dayton, OH
Click here to add this to my saved trials
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  8/9/2016
Clinical Research Facility
mi
from
Dallas, TX
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 8/9/2016
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  8/9/2016
Clinical Research Facility
mi
from
Wenatchee, WA
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 8/9/2016
Clinical Research Facility
mi
from
Wenatchee, WA
Click here to add this to my saved trials
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  8/9/2016
mi
from
Leuven,
Tecfidera Slow-titration Study
A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 8/9/2016
mi
from
Leuven,
Click here to add this to my saved trials
Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
Safety and Efficacy of ADS-5102 (Amantadine HCl) Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment
Status: Enrolling
Updated:  12/7/2016
Clinical Research Facility
mi
from
Phoenix, AZ
Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
Safety and Efficacy of ADS-5102 (Amantadine HCl) Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment
Status: Enrolling
Updated: 12/7/2016
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
Safety and Efficacy of ADS-5102 (Amantadine HCl) Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment
Status: Enrolling
Updated:  12/7/2016
Clinical Research Facility
mi
from
Sarasota, FL
Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
Safety and Efficacy of ADS-5102 (Amantadine HCl) Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment
Status: Enrolling
Updated: 12/7/2016
Clinical Research Facility
mi
from
Sarasota, FL
Click here to add this to my saved trials
Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
Safety and Efficacy of ADS-5102 (Amantadine HCl) Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment
Status: Enrolling
Updated:  12/7/2016
Clinical Research Facility
mi
from
Atlanta, GA
Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
Safety and Efficacy of ADS-5102 (Amantadine HCl) Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment
Status: Enrolling
Updated: 12/7/2016
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
Safety and Efficacy of ADS-5102 (Amantadine HCl) Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment
Status: Enrolling
Updated:  12/7/2016
Clinical Research Facility
mi
from
Northbrook, IL
Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
Safety and Efficacy of ADS-5102 (Amantadine HCl) Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment
Status: Enrolling
Updated: 12/7/2016
Clinical Research Facility
mi
from
Northbrook, IL
Click here to add this to my saved trials
Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
Safety and Efficacy of ADS-5102 (Amantadine HCl) Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment
Status: Enrolling
Updated:  12/7/2016
Clinical Research Facility
mi
from
Rochester, MN
Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
Safety and Efficacy of ADS-5102 (Amantadine HCl) Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment
Status: Enrolling
Updated: 12/7/2016
Clinical Research Facility
mi
from
Rochester, MN
Click here to add this to my saved trials
Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
Safety and Efficacy of ADS-5102 (Amantadine HCl) Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment
Status: Enrolling
Updated:  12/7/2016
Clinical Research Facility
mi
from
Patchogue, NY
Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
Safety and Efficacy of ADS-5102 (Amantadine HCl) Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment
Status: Enrolling
Updated: 12/7/2016
Clinical Research Facility
mi
from
Patchogue, NY
Click here to add this to my saved trials
Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
Safety and Efficacy of ADS-5102 (Amantadine HCl) Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment
Status: Enrolling
Updated:  12/7/2016
Clinical Research Facility
mi
from
Raleigh, NC
Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
Safety and Efficacy of ADS-5102 (Amantadine HCl) Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment
Status: Enrolling
Updated: 12/7/2016
Clinical Research Facility
mi
from
Raleigh, NC
Click here to add this to my saved trials
Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
Safety and Efficacy of ADS-5102 (Amantadine HCl) Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment
Status: Enrolling
Updated:  12/7/2016
Clinical Research Facility
mi
from
Franklin, TN
Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
Safety and Efficacy of ADS-5102 (Amantadine HCl) Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment
Status: Enrolling
Updated: 12/7/2016
Clinical Research Facility
mi
from
Franklin, TN
Click here to add this to my saved trials
Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
Safety and Efficacy of ADS-5102 (Amantadine HCl) Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment
Status: Enrolling
Updated:  12/7/2016
Clinical Research Facility
mi
from
Dallas, TX
Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
Safety and Efficacy of ADS-5102 (Amantadine HCl) Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment
Status: Enrolling
Updated: 12/7/2016
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
Safety and Efficacy of ADS-5102 (Amantadine HCl) Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment
Status: Enrolling
Updated:  12/7/2016
Clinical Research Facility
mi
from
Kirkland, WA
Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
Safety and Efficacy of ADS-5102 (Amantadine HCl) Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment
Status: Enrolling
Updated: 12/7/2016
Clinical Research Facility
mi
from
Kirkland, WA
Click here to add this to my saved trials
Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
Safety and Efficacy of ADS-5102 (Amantadine HCl) Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment
Status: Enrolling
Updated:  12/7/2016
Clinical Research Facility
mi
from
Aurora, CO
Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
Safety and Efficacy of ADS-5102 (Amantadine HCl) Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment
Status: Enrolling
Updated: 12/7/2016
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
Safety and Efficacy of ADS-5102 (Amantadine HCl) Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment
Status: Enrolling
Updated:  12/7/2016
Clinical Research Facility
mi
from
Lincoln, NE
Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
Safety and Efficacy of ADS-5102 (Amantadine HCl) Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment
Status: Enrolling
Updated: 12/7/2016
Clinical Research Facility
mi
from
Lincoln, NE
Click here to add this to my saved trials
Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
Safety and Efficacy of ADS-5102 (Amantadine HCl) Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment
Status: Enrolling
Updated:  12/7/2016
Clinical Research Facility
mi
from
Albuquerque, NM
Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
Safety and Efficacy of ADS-5102 (Amantadine HCl) Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment
Status: Enrolling
Updated: 12/7/2016
Clinical Research Facility
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
Safety and Efficacy of ADS-5102 (Amantadine HCl) Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment
Status: Enrolling
Updated:  12/7/2016
Clinical Research Facility
mi
from
Cleveland, OH
Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
Safety and Efficacy of ADS-5102 (Amantadine HCl) Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment
Status: Enrolling
Updated: 12/7/2016
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
Safety and Efficacy of ADS-5102 (Amantadine HCl) Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment
Status: Enrolling
Updated:  12/7/2016
Clinical Research Facility
mi
from
Oklahoma City, OK
Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
Safety and Efficacy of ADS-5102 (Amantadine HCl) Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment
Status: Enrolling
Updated: 12/7/2016
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort
The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort
Status: Enrolling
Updated:  12/12/2016
Carolinas Medical Center NorthEast Medical Arts Building
mi
from
Concord, NC
The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort
The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort
Status: Enrolling
Updated: 12/12/2016
Carolinas Medical Center NorthEast Medical Arts Building
mi
from
Concord, NC
Click here to add this to my saved trials
The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort
The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort
Status: Enrolling
Updated:  12/12/2016
Ada Jenkins Center
mi
from
Davidson, NC
The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort
The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort
Status: Enrolling
Updated: 12/12/2016
Ada Jenkins Center
mi
from
Davidson, NC
Click here to add this to my saved trials
The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort
The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort
Status: Enrolling
Updated:  12/12/2016
The Stedman Center on the Duke Center for Living Campus
mi
from
Durham, NC
The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort
The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort
Status: Enrolling
Updated: 12/12/2016
The Stedman Center on the Duke Center for Living Campus
mi
from
Durham, NC
Click here to add this to my saved trials
The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort
The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort
Status: Enrolling
Updated:  12/12/2016
Kannapolis Internal Medicine
mi
from
Kannapolis, NC
The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort
The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort
Status: Enrolling
Updated: 12/12/2016
Kannapolis Internal Medicine
mi
from
Kannapolis, NC
Click here to add this to my saved trials
The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort
The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort
Status: Enrolling
Updated:  12/12/2016
Raleigh Neurology Associates
mi
from
Raleigh, NC
The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort
The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort
Status: Enrolling
Updated: 12/12/2016
Raleigh Neurology Associates
mi
from
Raleigh, NC
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
HOPE Research Institute
mi
from
Phoenix, AZ
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
HOPE Research Institute
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated:  1/9/2017
Northwest NeuroSpecialists, PLLC
mi
from
Tucson, AZ
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis
Status: Enrolling
Updated: 1/9/2017
Northwest NeuroSpecialists, PLLC
mi
from
Tucson, AZ
Click here to add this to my saved trials